EGR2

Across TCGA pan-cancer cohorts, EGR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EGR2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EGR2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EGR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, BRCA, and LIHC are the cancer types where EGR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.373	0.699	.005	35	view →
BRCA	DFS	Median	IV	0.175	0.730	.005	18	view →
LIHC	DFS	Median	II,III,IV	0.040	0.427	<.001	12	view →
READ	OS	Median	III,IV	0.328	0.751	.003	6	view →
UCEC	DFS	Median	All	0.952	0.828	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EGR2–HNSC (DFS)

Open the HNSC breakdown →